

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office United States Patent and Trademark O Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

www.uspto.go

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/802,779	03/08/2001	James E. Hildreth	JHU1710-3	9936	
28213	7590 08/24/2004		EXAMINER		
	WARE & FREIDENR	LEWIS, PATRICK T			
4365 EXECUTI SUITE 1100	VE DRIVE	ART UNIT	PAPER NUMBER		
SAN DIEGO, C.	A 92121-2133		1623		
			DATE MAILED: 08/24/200-	4	

Notice of Fee Increase on October 1, 2004

If a reply to a "Notice of Allowance and Fee(s) Due" is filed in the Office on or after October 1, 2004, then the amount due will be higher than that set forth in the "Notice of Allowance and Fee(s) Due" because an increase in fees effective on October 1, 2004 is anticipated. See Revision of Patent Fees for Fiscal Year 2005; Proposed Rule, 69 Fed. Reg. 25861, 25863, 25864 (May 10, 2004).

The current fee schedule is accessible from WEB site (http://www.uspto.gov/main/howtofees.htm).

If the fee paid is the amount shown on the "Notice of Allowance and Fee(s) Due" but not the correct amount in view of the fee increase, a "Notice of Pay Balance of Issue Fee" will be mailed to applicant. In order to avoid processing delays associated with mailing of a "Notice of Pay Balance of Issue Fee," if the response to the Notice of Allowance is to be filed on or after October 1, 2004 (or mailed with a certificate of mailing on or after October 1, 2004), the issue fee paid should be the fee that is required at the time the fee is paid. See Manual of Patent Examining Procedure (MPEP), Section 1306 (Eighth Edition, Rev. 2, May 2004). If the issue fee was previously paid, and the response to the "Notice of Allowance and Fee(s) Due" includes a request to apply a previously-paid issue fee to the issue fee now due, then the difference between the issue fee amount at the time the response is filed and the previously-paid issue fee should be paid. See MPEP Section 1308.01.

Effective October 1, 2004, 37 CFR 1.18 is proposed to be amended by revising paragraphs (a) through (c) to read as set forth below. As stated above, the final fee may be a different amount, and applicant should check the WEB site given above when paying the fee.

Section 1.18 Patent post allowance (including issue) fees.

(a) Issue fee for issuing each original or reis	ssue patent,
except a design or plant patent:	
Py a small entity (Sec. 1.27(a))	\$670.00

by a sman entity (Sec. 1.27(a))	\$670.00
By other than a small entity	\$1,340.00
(b) Issue fee for issuing a design patent:	
By a small entity (Sec. 1.27(a))	\$245.00
By other than a small entity	\$490.00
(c) Issue fee for issuing a plant patent:	
By a small entity (Sec. 1.27(a))	\$325.00
By other than a small entity	\$650.00

Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at (703) 305-8283.

	Application No. Applicant(s)						
	09/802,779	HILDRETH, JAMES E.					
Notice of Allowability	Examiner	Art Unit					
	Patrick T. Lewis	1623					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. 1. This communication is responsive to May 26, 2004.							
2. X The allowed claim(s) is/are <u>1-15,19-30,33-37 and 49-51</u> .							
3. The drawings filed on are accepted by the Examiner.							
 4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted. 							
 (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 							
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.							
 Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☑ Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 08102004 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material 	6. ☑ Interview Summary Paper No./Mail Dat 8), 7. ☑ Examiner's Amendn	e <u>08162004</u> .					

Application/Control Number: 09/802,779

Art Unit: 1623

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Dr. Lisa Haile on August 16, 2004.

The application has been amended as follows:

- In claim 3, line 2, after the term "virus,", the term ---or--- has been inserted; in lines 2-3, the phrase ", a measles virus, or an influenza virus" has been deleted.
- In claim 14, line 2, the phrase "a vaginal disk, or a condom" has been deleted and the phrase ---a sponge, a condom, a bioadhesive polymer, a vaginal disk, a diaphram, a glove, a pellet, a tablet, or a tampon---- has been inserted therefor.
- In claim 20, line 1, after the term "virus,", the term ---or--- has been inserted; in lines 2-3, the phrase ", a measles virus, or an influenza virus" has been deleted.
- In claim 29, line 2, the phrase "a bioadhesive polymer, a vaginal disk, or a condom" has been deleted and the phrase ---a film, a sponge, a condom, a bioadhesive polymer, a vaginal disk, a diaphram, a glove, a pellet, a tablet, or a tampon----has been inserted therefor.
- In claim 34, line 2, after the term "virus,", the term ---or--- has been inserted; in lines 2-3, the phrase ", a measles virus, or an influenza virus" has been deleted.

Application/Control Number: 09/802,779

Art Unit: 1623

In claim 37, line 1, the phrase "A pharmaceutical composition consisting essentially of" has been deleted and the phrase ---The method as in any of claims 1, 9, or 23, wherein the β-cyclodextrin is present in--- has been inserted therefor; in line 2, the term "β-cyclodextrin" has been deleted.

Claims 40-47 have been canceled.

In claim 49, line 1, the phrase "The pharmaceutical composition of claim 37," has been deleted and the phrase ---The method as in any of claims 1, 9 or 23,--- has been inserted therefor.

In claim 50, line 1, the phrase "The composition of claim 40," has been deleted and the phrase ---The method as in any of claims 1, 9 or 23,--- has been inserted therefor.

In claim 51, line 1, the phrase "The composition of claim 40," has been deleted and the phrase ---The method as in any of claims 1, 9 or 23,--- has been inserted therefor.

Claims 52-56 and 59-61 have been deleted.

Application/Control Number: 09/802,779

Art Unit: 1623

Contacts

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patrick T. Lewis whose telephone number is 571-272-0655. The examiner can normally be reached on M-F 10:00 am to 3:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Patrick T. Lewis, PhD Examiner Art Unit 1623 Dr. Samuel Barts

Primary Patent Examiner Technology Center 1600

ptl